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The rapid increase in costs in medicine has highlighted the 
affordability and value of medical treatments.[1] Affordability is the 
cost relative to the amount that the purchaser is able to pay. Value is 
the ratio of patient benefit to cost.
A topical issue is the affordability and value of adjuvant 
trastuzumab for 1 year after surgery for localised human epidermal 
growth factor receptor 2 (HER2)-positive breast cancer, particularly 
in low- and middle-income countries. Affordability and value differ 
in patient groups with different baseline prognoses. This is illustrated 
below using the hazard ratio (HR) of survival rates obtained from a 
Cochrane review[2] and personal communication with Roche.
The HR is the ratio of the relative survival of two patient groups, 
with and without the test therapy. This ratio will not vary much 
over time. Patients can be divided into prognostic groups with 
different outcomes, depending on tumour stage and nodal status. 
For an assessment of affordability, a specific time point needs to be 
determined for the calculation of baseline survival. Expected baseline 
survival rates (BLSRs) for periods up to 15 years can be determined 
with breast cancer outcome calculators, which are available on 
the internet (e.g. https://www.adjuvantonline.com/ and http://www.
lifemath.net/cancer/breastcancer/therapy).
Number needed to treat (NNT) to 
benefit one patient at any selected 
endpoint
For clinical purposes, this may be approximated from the BLSR and 
the HR. The HR for overall survival in the calculation below was 0.69 
(95% confidence interval (CI) 0.58 - 0.81).
• The number of patients who will benefit when 100 patients are 
treated = (100 – BLSR) × (1 – HR).
• Therefore, for a BLSR survival rate of 90%, the number who will 
benefit = 10 × 0.31 = 3. The survival rate therefore increases from 
90% to 93%.
• The NNT to benefit one patient = 100/3 = 33.
More accurate numbers can be determined using more sophisticated 
formulae.[3]
Toxicity
The relative risk (RR) for increased toxicity for congestive heart 
failure = 5.11 (90% CI 3.00 - 8.72), and for decrease in left ventricular 
ejection fraction = 1.83 (90% CI 1.36 - 2.47).
Toxicity risk occurs in all treated patients, which means that the 
higher the BLSR, the higher is the proportion of patients who are free 
of disease who are exposed to potential toxicity. The toxicity also has 
cost implications, as all patients need to have their left ventricular 
function evaluated objectively with an echocardiogram or multigated 
acquisition (MUGA) scan every 3 months while on treatment.
The drug costs for 1 year on adjuvant 
trastuzumab
This analysis will restrict itself to a review of immediate drug costs 
alone, which are the largest cost factor. It excludes costs related to 
the facility fee, professional fees or associated investigations. A full 
economic analysis will include these costs as well as downstream 
costs for possible toxicity and savings from benefit.
The drug cost of 17 cycles of trastuzumab, allowing for vial 
sharing, for 1 year is ZAR413 000.
There are proponents for the use of adjuvant trastuzumab in all 
scenarios. The NNT to benefit one patient at a selected endpoint and 
the related drug cost to benefit one patient are shown in Table 1. The 
table indicates that the drug cost to benefit one patient ranges from 
ZAR13 752 900 (BLSR 90%) to ZAR4 006 100 (BLSR 60%).
Clinical ethics
It is a principle of clinical ethics that the clinician should provide 
the best treatment possible with available resources, provided there 
is evidence of benefit and the clinician is prepared to undertake the 
treatment.
In the Cochrane analysis,[2] the comment is made that the data 
indicate that the same efficacy is achieved with <6 months of 
treatment compared with 12 months of treatment and that there is 
less cardiac toxicity, but that this is not statistically significant with the 
numbers in the relevant studies. These studies are underpowered and 
there is relatively little incentive to undertake them. Although this is 
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a lower level of evidence compared with 
that found with higher numbers, it is not an 
absence of evidence. Where funders are not 
able to provide 12 months of trastuzumab, as 
happens at present in state institutions and 
the lower-level medical schemes, <6 months 
of trastuzumab should be considered as a 
treatment option to benefit patients.
Clinicians rightly wish to extend the benefits 
from advances in cancer treatment to all 
suitable patients. This requires an appre-
ciation of the costs involved and an ongoing 
engagement of state and healthcare institu-
tions and the pharmaceutical industry.
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Table 1. NNT to benefit one patient and the related drug costs with adjuvant 
trastuzumab in patients with breast cancer[3]
Patient baseline 
survival rate, %
Survival rate with 
trastuzumab, % 
NNT to benefit 
one patient
Drug cost (ZAR) to 
benefit one patient
90 93 33.4 13 794 200
80 86 17.5 7 227 500 
70 78 12.2 5 038 600
60 70 9.7 4 006 100
